Liu HaiYan, Zhang DongMei, Xu Xiao, Liu XiaoDong, Wang GuangJi, Xie Lin, Pang XiaoYan, Liu Li
Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Eur J Pharmacol. 2007 Apr 30;561(1-3):226-32. doi: 10.1016/j.ejphar.2007.01.062. Epub 2007 Feb 8.
The aim of the study was to investigate whether diabetes mellitus modulated the function and expression of P-glycoprotein and the distribution of phenobarbital in the brain of 3-week streptozotocin-induced diabetic mice. P-glycoprotein function in blood-brain barrier was assessed by measuring the brain-to-plasma concentration ratios of rodamine123, a well-known P-glycoprotein substrate, in non-diabetic mice and diabetic mice. P-glycoprotein expression in the brain cortex was evaluated with western blot. Whether diabetes mellitus changed the distribution of phenobarbital (60 mg/kg, i.v.) in brain of mice was measured, and whether the changed distribution caused the difference of phenobarbital (80 and 100 mg/kg) -induced loss of the righting reflex in non-diabetic and diabetic mice were also investigated. The results showed that the brain-to-plasma concentration ratio value of rodamine123 in diabetic mice was significantly higher than that of non-diabetic mice, western blot suggested that the protein level of P-glycoprotein in the brain of 3-week diabetic mice was significantly lower than that of non-diabetic mice, and insulin treatment restored the impairment of P-glycoprotein. The exposure of phenobarbital in brain of diabetic mice was 1.30-fold of that of non-diabetic mice, while in plasma the fold was 1.09. The increased distribution of phenobarbital in the brain of diabetic mice significantly increased the duration of phenobarbital-induced loss of the righting reflex and reduced the latency time of loss of the righting reflex. All the results suggested that the function and expression of P-glycoprotein might be impaired and the brain distribution of phenobarbital was increased in brain of streptozotocin-induced diabetic mice.
本研究旨在探讨糖尿病是否会调节链脲佐菌素诱导的3周龄糖尿病小鼠脑中P-糖蛋白的功能和表达以及苯巴比妥的分布。通过测量著名的P-糖蛋白底物罗丹明123在非糖尿病小鼠和糖尿病小鼠中的脑-血浆浓度比,评估血脑屏障中P-糖蛋白的功能。用蛋白质免疫印迹法评估大脑皮层中P-糖蛋白的表达。测定糖尿病是否改变了小鼠脑中苯巴比妥(60mg/kg,静脉注射)的分布,还研究了这种分布变化是否导致非糖尿病和糖尿病小鼠中苯巴比妥(80和100mg/kg)诱导的翻正反射消失的差异。结果显示,糖尿病小鼠中罗丹明123的脑-血浆浓度比值显著高于非糖尿病小鼠,蛋白质免疫印迹法表明,3周龄糖尿病小鼠脑中P-糖蛋白的蛋白水平显著低于非糖尿病小鼠,胰岛素治疗可恢复P-糖蛋白的损伤。糖尿病小鼠脑中苯巴比妥的暴露量是非糖尿病小鼠的1.30倍,而血浆中的倍数为1.09。糖尿病小鼠脑中苯巴比妥分布的增加显著延长了苯巴比妥诱导的翻正反射消失的持续时间,并缩短了翻正反射消失的潜伏期。所有结果表明,链脲佐菌素诱导的糖尿病小鼠脑中P-糖蛋白的功能和表达可能受损,苯巴比妥的脑部分布增加。